Sinopharm Group Co., Ltd.

Market Cap: N/A
Industry: Retailing
ISIN: CNE100000FN7

HKD

17.55

0.03 (0.17%)

May 22

HKG

View all stocks in this country

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sino Biopharmaceutical Ltd.

WuXi AppTec Co., Ltd.

China Medical System Holdings Ltd.

Sinopharm Group Co., Ltd.

China Resources Pharmaceutical Group Ltd.

Hygeia Healthcare Holdings Co., Ltd.

Hansoh Pharmaceutical Group Co., Ltd.

Innovent Biologics, Inc.

Akeso, Inc.

HUTCHMED (China) Ltd.

BeiGene Ltd.

Why is Sinopharm Group Co., Ltd. ?

The company is Net-Debt Free

The company is Net-Debt Free

High Debt company with Weak Long Term Fundamental Strength

Flat results in Dec 25

OPERATING CASH FLOW(Y) Lowest at HKD 9,280.33 MM
RAW MATERIAL COST(Y) Grown by 21.93% (YoY)

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -4.52% returns in the last 1 year, the stock has also underperformed Hang Seng Hong Kong in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Retailing)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sinopharm Group Co., Ltd. for you?

Low Risk, High Return

Absolute

Risk Adjusted

Volatility

Sinopharm Group Co., Ltd.

-4.52%

19.57

20.51%

Hang Seng Hong Kong

8.76%

0.45

19.63%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

5.58%

EBIT Growth (5y)

-0.84%

EBIT to Interest (avg)

5.74

Debt to EBITDA (avg)

1.71

Net Debt to Equity (avg)

0.57

Sales to Capital Employed (avg)

3.07

Tax Ratio

27.95%

Dividend Payout Ratio

31.99%

Pledged Shares

Institutional Holding

0.02%

ROCE (avg)

18.45%

ROE (avg)

19.69%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.74

EV to EBIT

8.38

EV to EBITDA

6.54

EV to Capital Employed

0.87

EV to Sales

0.24

PEG Ratio

Dividend Yield

3.35%

ROCE (Latest)

10.34%

ROE (Latest)

12.98%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

DEBT-EQUITY RATIO (HY)

Lowest at 46.12 %

-3What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at HKD 9,280.33 MM

RAW MATERIAL COST(Y)

Grown by 21.93% (YoY

Here's what is working for Sinopharm Group Co., Ltd.

Debt-Equity Ratio

Lowest at 46.12 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Sinopharm Group Co., Ltd.

Operating Cash Flow

Lowest at HKD 9,280.33 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (HKD MM)

Raw Material Cost

Grown by 21.93% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales